Biotron Share Price Shoots 26% Higher on Preliminary COVID-19 Results

By ,

The hunt for a COVID-19 vaccine is ramping up.

We learnt yesterday that the government has spent $1.7 billion on potential treatments. Hedging their bets on some $84 million worth of doses that will be ready for free rollouts by 2021.

Whether or not these vaccines will work though, is unclear.

It is simply the government’s way of trying to get ahead of the masses. A gamble that could pay off in spades or prove to be a massive waste of money…

Either way though, it highlights the incredible opportunity surrounding biotech stocks right now. Particularly those that are looking for or serving up potential COVID-19 solutions.

Which is precisely what Biotron Ltd [ASX:BIT] has done today.

A small-cap stock that is up 26.32% at time of writing, the BIT share price moved up on the announcement. Surging on the back of some fascinating findings regarding compounds that could fight against the ‘rona.

Promising find

See Biotron is tackling the coronavirus from a different angle.

Rather than trying to cure the virus, they are looking for ways to destroy it. Using a unique set of compounds that have shown some promise in cell protection and killing the virus itself.

After testing some 47 compounds, 15 showed potential. Meeting the key endpoints set out by the trial and providing the groundwork for further testing.

As Biotron’s Managing Director Michelle Miller commented:

The results to date are encouraging. There is a need for new ways to treat this disease, and Biotron believes that these results open up a promising new therapeutic pathway.

The results underscore the versatility of Biotron’s approach to designing and developing drugs to target serious virus infections.

However, these are still very early stages for Biotron.

Any chances of producing a successful solution for the COVID-19 virus will require much further testing. Meaning that this small biotech still has a long road ahead of itself.

Nevertheless, it is fantastic to see such promising potential.

Major breakthroughs needed

For investors, this development is certainly welcome news.

If Biotron sticks with it, they could be onto a real winner. A strategy that may help them address many diseases and viruses into the future, not just COVID-19.

Again though, we will only find out in due time.

It does, however, serve as a reminder as to the potential that can be found on the market right now.

Biotron showcases the kind of small-cap breakthrough potential that is out there. Going toe-to-toe with far larger and better capitalised companies.

But, all it takes is one successful trial or one major discovery to strike it rich. The kind of breakthrough that isn’t just exclusive to biotech stocks.

For instance, take our report on three explosive tech plays; a deeper look at what may be the best hidden gems on the ASX right now.

Learn all about these three small-caps, and the sectors behind them, right here.


Ryan Clarkson-Ledward,
For Money Morning

About Ryan Clarkson-Ledward

Ryan Clarkson-Ledward is an Editor at Money Morning.

Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects.

Ryan is also the Editor…

Three Stocks to Watch during the Coronavirus Rollercoaster

Market volatility is continuing to rise amidst the ongoing global pandemic. Worst yet, it is difficult to pinpoint when this is likely to end. Markets are up one day and crashing down the next. It is a telling sign when investors begin to look for safety among some of Australia’s most speculative small-caps…

A Look at the Orthocell Share Price: Can It Keep Going Up? 

Despite a recent pullback, it has been an exciting ride for investors with the Orthocell share price going through the roof on 8 May .Today we will be looking at what caused Orthocell’s remarkable rise and its prospects going forward. 

Biotron Share Price Up, Letter to Shareholders Includes Useful Information

Early this morning, the share price of Biotron Limited [ASX:BIT] managed to spike up 7.69%, trading at 14 cents per share. In a letter to the shareholders, the company disclosed a couple of useful pieces of information.

Biotron Share Price Volatile as Investors Digest Latest Release

It’s been a rollercoaster ride for the Biotron Limited [ASX:BIT] share price, with the stock up 14.82% today, trading at $.155 at time of writing. Reasons for the current volatility are hard to pin down, but profit-taking and new data released by the company could be factors. The Biotron share price is down from a high of … Read More

Biotron Share Price Up as it Responds to ASX Query

The share price of Biotron is up 9.5% and trading at $0.115, at time of writing. It has been an exciting time for Biotron shareholders who, last month, could have sold their shares for a whopping $0.445.

Huge Gains for Biotron Share Price After Promising HIV Drug Trial Results

In just the past three trading days Biotron Limited [ASX:BIT] has rocketed up. As at time of writing, it’s trading at $.093, a 489% increase from three trading days ago where it closed at $.019. Biotron is a biotechnology research company working on a range of antiretroviral drugs. Antiretroviral drugs fight viruses, and Biotron has … Read More